- Home
- LLY vs JPM Comparison
LLY vs JPM Comparison
Compare LLY & JPM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LLY | JPM |
|---|---|---|
| Founded | 1876 | 1799 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 994.5B | 900.8B |
| IPO Year | 2007 | 2025 |
Fundamental Metrics
Financial Performance| Metric | LLY | JPM |
|---|---|---|
| Price | $1,158.14 | $331.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 30 | 24 |
| Target Price | ★ $1,328.83 | $372.81 |
| AVG Volume (30 Days) | 1.4M | ★ 6.3M |
| Earning Date | 10-29-2026 | 10-13-2026 |
| Dividend Yield | 0.61% | ★ 1.99% |
| EPS Growth | ★ 95.99 | 1.37 |
| EPS | ★ 16.19 | 13.63 |
| Revenue | $65,179,000,000.00 | ★ $182,447,000,000.00 |
| Revenue This Year | $35.77 | $14.38 |
| Revenue Next Year | $15.43 | $2.82 |
| P/E Ratio | $70.66 | ★ $24.38 |
| Revenue Growth | ★ 44.70 | 2.75 |
| 52 Week Low | $783.85 | $279.10 |
| 52 Week High | $1,292.65 | $366.50 |
Technical Indicators
Market Signals| Indicator | LLY | JPM |
|---|---|---|
| Relative Strength Index (RSI) | 48.28 | 32.90 |
| Support Level | $1,118.95 | $323.83 |
| Resistance Level | $1,190.26 | $337.25 |
| Average True Range (ATR) | 29.64 | 5.76 |
| MACD | 0.52 | -1.40 |
| Stochastic Oscillator | 39.95 | 20.33 |
Price Performance
Historical ComparisonAbout LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
About JPM JP Morgan Chase & Co.
JPMorgan is a leading global financial services firm with operations in 66 countries and over 318,000 employees as of year-end 2025. Under the JPMorgan brands, the bank holding company boasts a $4.9 trillion balance sheet and $2.68 trillion in deposits, as of March 2026. The firm generates its revenue across three core operating segments: consumer and community banking, the commercial and investment bank, and asset and wealth management. It maintains the top global ranking in investment banking fees with an 8.4% market share, serves millions of consumers through its network of over 5,000 US branches, and manages over $7.1 trillion in client assets within its wealth and asset management franchise.